Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management.

Fone KCF, Watson DJG, Billiras RI, Sicard DI, Dekeyne A, Rivet JM, Gobert A, Millan MJ.

Mol Neurobiol. 2020 Jan 20. doi: 10.1007/s12035-020-01875-9. [Epub ahead of print]

PMID:
31960362
2.

5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia.

Meffre J, Chaumont-Dubel S, Mannoury la Cour C, Loiseau F, Watson DJ, Dekeyne A, Séveno M, Rivet JM, Gaven F, Déléris P, Hervé D, Fone KC, Bockaert J, Millan MJ, Marin P.

EMBO Mol Med. 2012 Oct;4(10):1043-56. doi: 10.1002/emmm.201201410.

3.

S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization.

Dekeyne A, Brocco M, Loiseau F, Gobert A, Rivet JM, Di Cara B, Cremers TI, Flik G, Fone KC, Watson DJ, Papp M, Sharp T, Serres F, Cespuglio R, Olivier B, Chan JS, Lavielle G, Millan MJ.

J Pharmacol Exp Ther. 2012 Mar;340(3):765-80. doi: 10.1124/jpet.111.187534. Epub 2011 Dec 16.

PMID:
22178753
4.

S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.

Millan MJ, Mannoury la Cour C, Chanrion B, Dupuis DS, Di Cara B, Audinot V, Cussac D, Newman-Tancredi A, Kamal M, Boutin JA, Jockers R, Marin P, Bockaert J, Muller O, Dekeyne A, Lavielle G.

J Pharmacol Exp Ther. 2012 Mar;340(3):750-64. doi: 10.1124/jpet.111.187468. Epub 2011 Dec 16.

PMID:
22178752
5.

Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: a comparison to melatonin and to the 5-HT(2c) antagonist, S32006.

Norman TR, Cranston I, Irons JA, Gabriel C, Dekeyne A, Millan MJ, Mocaër E.

Eur J Pharmacol. 2012 Jan 5;674(1):27-32. doi: 10.1016/j.ejphar.2011.10.010. Epub 2011 Oct 21.

PMID:
22040921
6.

S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant (MK869) and paroxetine.

Millan MJ, Dekeyne A, Gobert A, Mannoury la Cour C, Brocco M, Rivet JM, Di Cara B, Lejeune F, Cremers TI, Flik G, de Jong TR, Olivier B, de Nanteuil G.

Eur Neuropsychopharmacol. 2010 Sep;20(9):599-621. doi: 10.1016/j.euroneuro.2010.04.003. Epub 2010 May 18.

PMID:
20483567
7.

Neurokinin1 antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions: a neurochemical, electrophysiological, and behavioral characterization.

Gobert A, Brocco M, Dekeyne A, Di Cara B, Bouchez G, Lejeune F, Gannon RL, Millan MJ.

Neuropsychopharmacology. 2009 Mar;34(4):1039-56. doi: 10.1038/npp.2008.176. Epub 2008 Oct 1.

8.

Discriminative stimulus properties of the atypical antidepressant, mirtazapine, in rats: a pharmacological characterization.

Dekeyne A, Millan MJ.

Psychopharmacology (Berl). 2009 Apr;203(2):329-41. doi: 10.1007/s00213-008-1259-8. Epub 2008 Aug 16.

PMID:
18709360
9.

Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents.

Brocco M, Dekeyne A, Mannoury la Cour C, Touzard M, Girardon S, Veiga S, de Nanteuil G, deJong TR, Olivier B, Millan MJ.

Eur Neuropsychopharmacol. 2008 Oct;18(10):729-50. doi: 10.1016/j.euroneuro.2008.06.002. Epub 2008 Jul 26.

PMID:
18657401
10.

S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.

Dekeyne A, Mannoury la Cour C, Gobert A, Brocco M, Lejeune F, Serres F, Sharp T, Daszuta A, Soumier A, Papp M, Rivet JM, Flik G, Cremers TI, Muller O, Lavielle G, Millan MJ.

Psychopharmacology (Berl). 2008 Sep;199(4):549-68. doi: 10.1007/s00213-008-1177-9. Epub 2008 Jun 4.

PMID:
18523738
11.

The melanin-concentrating hormone1 receptor antagonists, SNAP-7941 and GW3430, enhance social recognition and dialysate levels of acetylcholine in the frontal cortex of rats.

Millan MJ, Gobert A, Panayi F, Rivet JM, Dekeyne A, Brocco M, Ortuno JC, Di Cara B.

Int J Neuropsychopharmacol. 2008 Dec;11(8):1105-22. doi: 10.1017/S1461145708008894. Epub 2008 May 9.

12.
13.

S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.

Millan MJ, Svenningsson P, Ashby CR Jr, Hill M, Egeland M, Dekeyne A, Brocco M, Di Cara B, Lejeune F, Thomasson N, Munoz C, Mocaër E, Crossman A, Cistarelli L, Girardon S, Iob L, Veiga S, Gobert A.

J Pharmacol Exp Ther. 2008 Feb;324(2):600-11. Epub 2007 Nov 16.

PMID:
18024787
14.

Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex.

Loiseau F, Dekeyne A, Millan MJ.

Psychopharmacology (Berl). 2008 Jan;196(1):93-104. Epub 2007 Oct 6.

PMID:
17922111
15.

Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis.

Millan MJ, Di Cara B, Dekeyne A, Panayi F, De Groote L, Sicard D, Cistarelli L, Billiras R, Gobert A.

J Neurochem. 2007 Feb;100(4):1047-61.

18.

Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.

Brocco M, Dekeyne A, Papp M, Millan MJ.

Behav Pharmacol. 2006 Nov;17(7):559-72.

PMID:
17021388
19.

Activation of dopamine D1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats.

Di Cara B, Panayi F, Gobert A, Dekeyne A, Sicard D, De Groote L, Millan MJ.

Int J Neuropsychopharmacol. 2007 Jun;10(3):383-99. Epub 2006 Aug 22.

21.
22.

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.

Millan MJ, Brocco M, Gobert A, Dekeyne A.

Psychopharmacology (Berl). 2005 Feb;177(4):448-58. Epub 2004 Jul 31.

PMID:
15289999
23.

The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis.

Millan MJ, Gobert A, Roux S, Porsolt R, Meneses A, Carli M, Di Cara B, Jaffard R, Rivet JM, Lestage P, Mocaer E, Peglion JL, Dekeyne A.

J Pharmacol Exp Ther. 2004 Oct;311(1):190-203. Epub 2004 May 14.

PMID:
15146031
24.

S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.

Millan MJ, Brocco M, Papp M, Serres F, La Rochelle CD, Sharp T, Peglion JL, Dekeyne A.

J Pharmacol Exp Ther. 2004 Jun;309(3):936-50. Epub 2004 Feb 20.

PMID:
14978196
25.

Discriminative stimulus properties of antidepressant agents: a review.

Dekeyne A, Millan MJ.

Behav Pharmacol. 2003 Sep;14(5-6):391-407. Review.

PMID:
14501253
26.

The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.

Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D.

J Pharmacol Exp Ther. 2003 Sep;306(3):954-64. Epub 2003 May 15.

PMID:
12750432
28.

Differential modulation of efficiency in a food-rewarded "differential reinforcement of low-rate" 72-s schedule in rats by norepinephrine and serotonin reuptake inhibitors.

Dekeyne A, Gobert A, Auclair A, Girardon S, Millan MJ.

Psychopharmacology (Berl). 2002 Jul;162(2):156-67. Epub 2002 May 1.

PMID:
12110993
29.

Stereospecific blockade of marble-burying behaviour in mice by selective, non-peptidergic neurokinin1 (NK1) receptor antagonists.

Millan MJ, Girardon S, Mullot J, Brocco M, Dekeyne A.

Neuropharmacology. 2002 Apr;42(5):677-84.

PMID:
11985826
30.

The selective serotonin(2A) receptor antagonist, MDL100,907, elicits a specific interoceptive cue in rats.

Dekeyne A, Iob L, Hautefaye P, Millan MJ.

Neuropsychopharmacology. 2002 Apr;26(4):552-6.

31.
32.

Improvement in the selectivity and metabolic stability of the serotonin 5-HT(1A) ligand, S 15535: a series of cis- and trans-2-(arylcycloalkylamine) 1-indanols.

Peglion JL, Goument B, Despaux N, Charlot V, Giraud H, Nisole C, Newman-Tancredi A, Dekeyne A, Bertrand M, Genissel P, Millan MJ.

J Med Chem. 2002 Jan 3;45(1):165-76.

PMID:
11754589
33.

Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats.

Dekeyne A, Gobert A, Iob L, Cistarelli L, Melon C, Millan MJ.

Psychopharmacology (Berl). 2001 Nov;158(2):213-8.

PMID:
11702096
34.

Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent.

Millan MJ, Brocco M, Gobert A, Dorey G, Casara P, Dekeyne A.

Neuropsychopharmacology. 2001 Oct;25(4):585-600.

35.

S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.

Millan MJ, Dekeyne A, Papp M, La Rochelle CD, MacSweeny C, Peglion JL, Brocco M.

J Pharmacol Exp Ther. 2001 Aug;298(2):581-91.

PMID:
11454919
37.
38.

S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine.

Millan MJ, Lejeune F, Gobert A, Brocco M, Auclair A, Bosc C, Rivet JM, Lacoste JM, Cordi A, Dekeyne A.

J Pharmacol Exp Ther. 2000 Dec;295(3):1206-22.

PMID:
11082458
39.

S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.

Millan MJ, Dekeyne A, Newman-Tancredi A, Cussac D, Audinot V, Milligan G, Duqueyroix D, Girardon S, Mullot J, Boutin JA, Nicolas JP, Renouard-Try A, Lacoste JM, Cordi A.

J Pharmacol Exp Ther. 2000 Dec;295(3):1192-205.

PMID:
11082457
41.

S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626.

Millan MJ, Dekeyne A, Rivet JM, Dubuffet T, Lavielle G, Brocco M.

J Pharmacol Exp Ther. 2000 Jun;293(3):1063-73.

PMID:
10869411
43.

Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram.

Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F.

Eur J Neurosci. 2000 Mar;12(3):1079-95.

PMID:
10762339
44.
45.

Citalopram reduces social interaction in rats by activation of serotonin (5-HT)(2C) receptors.

Dekeyne A, Denorme B, Monneyron S, Millan MJ.

Neuropharmacology. 2000 Apr 3;39(6):1114-7.

PMID:
10727723
46.
48.

Inverse agonists and serotonergic transmission: from recombinant, human serotonin (5-HT)1B receptors to G-protein coupling and function in corticolimbic structures in vivo.

Millan MJ, Gobert A, Audinot V, Dekeyne A, Newman-Tancredi A.

Neuropsychopharmacology. 1999 Aug;21(2 Suppl):61S-67S. Review.

49.

5-HT2C receptors are involved in the discriminative stimulus effects of citalopram in rats.

Millan MJ, Girardon S, Dekeyne A.

Psychopharmacology (Berl). 1999 Mar;142(4):432-4.

PMID:
10229070
50.

Supplemental Content

Loading ...
Support Center